The combination of cadonilimab (a PD-1/CTLA-4 bispecific antibody) and disitamab vedotin (an anti-HER2 antibody-drug conjugate) was selected based on the rationale that targeting HER2 amplification with disitamab vedotin, alongside immune checkpoint inhibition with cadonilimab, would provide a dual approach to target tumor cells and enhance antitumor immunity. The gene discussed is ERBB2; the disease is neoplasm.